Public Company Healthcare

Telix Pharmaceuticals

North Melbourne, Victoria, Australia

Global biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals (theranostics) for oncology and other indications, with associated medical devices and radiopharmaceutical production operations.

Focus Areas
Radiopharmaceuticals, Theranostics, Oncology therapeutics
Website
telixpharma.com

Tracked deals

3

3 tracked deals across 2024-2026.

Recent pace

1

1 tracked deal announced in the last 12 months.

Deal mix

Buyout

3 buyout

Telix Pharmaceuticals Acquisition Volume by Year

Last 2 years

Acquisition volume by year Annual acquisition counts for the last 2 years for Telix Pharmaceuticals. 2 2024 ~1 est. 1 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Telix Pharmaceuticals to Acquire ITM Isotope Technologies Munich to Build Radiopharmaceutical Powerhouse
    September 21, 2026
    Buyer
    Telix Pharmaceuticals
    Target
    ITM Isotope Technologies Munich
    Seller
    ITM sellers (not individually named in the article)
    Industry
    Pharmaceuticals
    Location
    Germany
    Type
    Buyout

    Telix Pharmaceuticals has signed an agreement to acquire 100% of ITM Isotope Technologies Munich in a deal valuing it at $1.65 billion upfront, with up to $700 million in additional milestone payments. The acquisition combines Telix’s radiopharmaceutical development and precision medicine capabilities with ITM’s large-scale isotope manufacturing, global distribution, and late-stage therapeutic pipeline, aiming to create a more vertically integrated radiopharmaceutical platform.

  • Telix Pharmaceuticals Acquires ARTMS Inc.
    March 5, 2024
    Buyer
    Telix Pharmaceuticals Limited
    Target
    ARTMS Inc.
    Industry
    Pharmaceuticals
    Location
    British Columbia, Canada
    Type
    Buyout

    Telix Pharmaceuticals Limited has completed the acquisition of ARTMS Inc., a Burnaby, British Columbia-based developer of cyclotron-based isotope production technology and the QUANTM Irradiation System (QIS). The deal strengthens Telix's vertical integration and supply-chain control for key diagnostic and therapeutic radioisotopes (including 89Zr, 68Ga, 99mTc and 64Cu) to support its commercial products and pipeline.

  • Telix Pharmaceuticals Acquires QSAM Biosciences
    February 8, 2024
    Buyer
    Telix Pharmaceuticals Limited
    Target
    QSAM Biosciences, Inc.
    Seller
    Checkmate Capital Group LLC, Strategic Planning Assets Limited
    Industry
    Biotechnology
    Location
    United States
    Type
    Buyout

    Telix Pharmaceuticals Limited has entered into an agreement to acquire QSAM Biosciences, Inc., adding QSAM's lead radiopharmaceutical candidate 153Sm-DOTMP (Samarium-153-DOTMP) to Telix's therapeutic pipeline. The asset expands Telix's oncology focus into bone-targeting radiopharmaceuticals with potential applications in pain management of bone metastases and osteosarcoma (including pediatric indications).

Related Acquisition Pages

Pharmaceuticals Buyers & Acquisitions 2 tracked deals by Telix Pharmaceuticals. Biotechnology Buyers & Acquisitions 1 tracked deal by Telix Pharmaceuticals.

Related articles

Selling a company? Get in front of buyers like Telix Pharmaceuticals

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →